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Mice with a  spontaneous disease that  approximates systemic lupus erythematosus 
(SLE) 1  have  marked  amounts  of  immune  complexes  (IC)  containing  the  major 
envelope glycoprotein, gp70, of endogenous retroviruses and the corresponding anti- 
body (1). These IC become apparent  in  the circulation close to the onset of disease, 
and concentrations rise as the disease worsens. Strains of mice without  this immuno- 
logic disease do not develop gp70-anti-gp70 IC (gp70 IC), at least in detectable levels. 
The observation that  gp70 deposits along with  host  immunoglobulin  (Ig)  and com- 
plement in the diseased glomeruli of SLE-prone mice seems to be good evidence that 
gp70  IC are one source of the renal lesions that  contribute to these animals' deaths 
(2,  3).  Additionally, the  involvement  of DNA-anti-DNA IC  in  the  pathogenesis of 
murine SLE was demonstrated by the significant concentration ofanti-DNA antibod- 
ies found  in eluates from the diseased kidneys of these mice (3, 4).  The induction of 
tolerance to DNA antigen in (NZB ×  NZW)F1 hybrid mice (NZB ×  W) was followed 
by decreased anti-DNA production, less severe nephritis, and  prolonged survival  (5, 
6). 
We  have  now  examined  the  importance  of  gp70  IC  and  anti-DNA  antibody 
formation in the renal disease of three murine strains (NZB ×  W, MRL/1  and BXSB) 
that are SLE-prone. For this purpose, we used prostaglandin E1  (PGE), which altered 
immunologically  mediated  renal  disease  and  prolonged  survival  without  affecting 
degree of anti-DNA formation, as established in a  previous study of NZB  ×  W  mice 
(7, 8). Our results indicate that  NZB  ×  W  and  MRL/1  mice treated with PGE  had 
far lower levels of circulating gp70  IC, amelioration of renal disease, and  increased 
survival  time  compared  with  untreated  controls.  However,  BXSB  mice  were  not 
responsive to PGE treatment, and life span and serum levels of gp70 IC in the treated 
mice were essentially identical to those in untreated mice. 
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Materials and Methods 
Mice.  NZB ×  W  female mice were obtained by mating NZB females with NZW males in 
our  animal colony.  MRL/1  (lpr/lpr)  and  BXSB  mice  originally came  from  The Jackson 
Laboratory, Bar Harbor, Maine, and were bred at Scripps Clinic and Research Foundation, 
La Jolla, Calif. Their blood samples were collected by orbital sinus puncture, and the sera were 
stored at -20°C until use. 
Treatment  with  PGE.  PGE,  which  was  generously supplied  by  Dr.  J.  Pike  of  Upjohn 
Company, Kalamazoo, Mich., and by Ono Pharmaceutical Company, Ltd., Osaka, Japan, was 
stored in absolute ethanol at -20°C and diluted daily with phosphate-buffered saline (PBS). 
The  final solution consisting of PGE  in  10%  ethanol-PBS at  pH  6.8  was spectroscopically 
analyzed to determine purity (9). Groups of 2-mo-old female mice were injected subcutaneously 
with 200 #g of PGE twice daily 5 d of the week and once each Saturday and Sunday throughout 
the course of experiment. Controls consisted of littermates receiving the vehicle alone. Groups 
of mice were killed bimonthly beginning  at 4 mo of age or when moribund and then autospied. 
Immunologic  Reagents.  Retroviral gp70 of Rauscher murine leukemia virus (MuLV)  were 
prepared as described by Strand and August (10) and goat anti-Rauscher MuLV gpT0 antisera 
were kindly provided by Dr. J.  Elder (Scripps Clinic and Research Foundation). Goat anti- 
feline leukemia virus antisera were obtained from the National Cancer Institute, Bethesda, Md. 
Rabbit anti-murine IgG antibodies were  raised  in rabbits by giving repeated  injections of 
murine IgG  (Miles  Laboratories  Inc.,  Elkhart,  Ind.).  IgG  fractions of these  antisera were 
prepared by DEAE-cellulose column chromatography. Fluorescein isothiocyanate-conjugated 
rabbit anti-murine IgG were obtained from Miles Laboratories, Inc., and goat anti-murine  C3 
antisera  were  purchased  from  N.  L.  Cappel  Laboratories,  Inc.,  Cochranville, Pa.  Highly 
polymerized calf thymus DNA (type V) was purchased from Sigma Chemical Co., St.  Louis, 
Mo. Protein A-containing  Staphylococcus aureus bacteria treated with formaldehyde were kindly 
provided by Dr. M. J. Buchmeier, Scripps Clinic and Research Foundation. Protein A-free S. 
aureus bacteria were obtained from Calbiochem-Behring Corp., American Hoechst Corp., La 
Jolla, Calif. 
Radiolabeling  Procedures.  gpT0 from Rauscher MuLV and the IgG fraction of rabbit anti- 
murine IgG were  labeled with  radioactive iodine (12~I) by the  chloramine T  method  (11). 
Single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA)  were labeled with 125I by 
the  method  of Commerford  (12). Then,  125I-dsDNA was  treated  with  SI  nuclease  (Miles 
Laboratories, Inc.) to remove single-strand regions within dsDNA (13). 
Morphologic Studies 
Tissues from PGE-treated mice and controls were  assessed for morphologic and immuno- 
pathologi  c changes by light, fluorescence,  and electron microscopy as previously described (8). 
LIGHT MICROSCOPY.  Sections  of  kidneys  were  fixed  in  Bouin's  fluid  and  stained  with 
hematoxylin and eosin and periodic acid-Schiff on coded slides. Renal histopathologic altera- 
tions were graded on a semi-quantitative scale  by criteria adopted from Pirani and Salinas- 
Madrigal (14). The scale ranged from 0 to 4: 0, normal; 0.5, minimal or questionable; 1, mild; 
2, moderate; 3, moderately severe; 4, severe alterations. 
IMMUNOFLUORESCENCE MICROSCOPY.  Renal tissues were studied for the deposition of IgG and 
gp70 by direct immunofluorescence after staining with fluorescein isothiocyanate-conjugated 
rabbit anti-murine IgG or goat anti-Rauscher MuLV gp70. The intensity and distribution of 
fluorescence were graded from 0 to 4. 
ELECTRON MICROSCOPY.  Kidney tissues  were  fixed  in  glutaraldehyde-paraformaldehyde, 
post-fixed  in osmic acid, dehydrated, embedded in Epon, sectioned, and stained with uranyl 
acetate and lead citrate. Renal pathologic alterations in at  least  two glomeruli/mouse were 
graded on a 0-4 scale (15). 
Elution of Kidney-fixedgp70 and Ig.  Renal eluates were prepared as described previously (16). 
Briefly,  kidneys from PGE-treated and control NZB  ×  W  mice were pooled, cut into small 
pieces, and washed extensively with PBS overnight at 4°C. The tissues were homogenized and 
washed five times by centrifugation in PBS.  The precipitates were resuspended in PBS that 
contained Mg  ++, digested with DNase, and eluted with 2.5 M potassium thiocyanate in PBS. 
The  eluates  obtained were  concentrated  with  a  Diaflo  uitrafihration membrane  (PM10; 
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amounts of anti-DNA antibodies in the eluates were determined by quantitative absorption 
with  cyanogen  bromide-activated  Sepharose  4B  coated  with  both  ssDNA  and  dsDNA  as 
described previously (16). 
Detection of Anti-DNA  Antibodies.  Serum levels of anti-DNA antibodies were determined by 
using a modification of the Farr DNA-binding radioimmunoassay (17). To inactivate IgM anti- 
DNA  antibodies,  sera  were  incubated  with  12SI-DNA and  2-mercaptoethanol  (2-ME;  final 
concentration of 0.1  M)  (18). The results are expressed as a  percentage of 20 ng of 125I-DNA 
precipitated  specifically  after  correction  for  nonspecific  precipitation  in  pooled  sera  from 
immunologically normal  mice of five different strains  (AKR, BALB/c, C3H, C57BL/6, and 
DBA/2). The Ig class  of anti-DNA antibodies was also analyzed by sucrose density-gradient 
uhracentrifugation (18). 
The avidity of anti-DNA antibodies was determined by measuring the dissociation rate of 
preformed 12SI-DNA-anti-DNA complexes in the presence of unlabeled DNA (19). Tubes that 
contained the pooled sera, which bind  ~40% of the added  12~I-DNA (20 ng), were incubated 
with ]25I-DNA at 4°C for 24 h. Then, a  100-fold excess of unlabeled DNA (2 p.g) was added to 
each tube,  and at  increasing intervals thereafter the serum DNA-binding activity was deter- 
mined as described above. Dissociation curves were then constructed by plotting log (Px/Po) 
X  100 against time, where Px is the fraction of t25I-DNA bound at time x and Po the fraction 
bound  at  time 0.  Because of the antibody heterogeneity, dissociation curves with  anti-DNA 
antibodies were resolved into high- and low-avidity components by curve peeling. 
Radioimmunoassaysfor Circulating DNA-Anti-DNA IC.  Three different procedures were used to 
detect DNA-anti-DNA IC in sera.  First, serum DNA-binding activity was measured before and 
after  treatment  of sera  with  DNase,  which  liberates  anti-DNA  antibodies  bound  to  DNA 
resulting in the increase of DNA-binding activity (20). The detail of this procedure has been 
described previously (18). Second, the presence of rapidly sedimenting anti-DNA complexes 
was analyzed by the sucrose density-gradient ultracentrifugation according to the method of 
Bruneau  and  Benveniste (21).  Last,  [3H]actinomycin  D,  which specifically binds  DNA, was 
used to detect DNA bound to anti-DNA antibodies as described previously (22). 
Radioimmunoassayfor Circulating 1C.  IC in sera of all test mice were detected and quantitated 
with a modified Raji cell radioimmunoassay (3). Aggregated murine IgG (AMG) was used for 
the standard  curve and  the  [25I-labeled  IgG fracti0n  of rabbit  anti-murine IgG was used  to 
quantitate  Raji cell-bound IgG.  Pooled  BALB/c serum  stored  at  -70°C  was  the  source of 
complement in the standard curve. Results are expressed as microgram equivalents of AMG/ 
ml murine serum. The upper normal limit of IC in the sera of 20 #g equivalent AMG/ml was 
based on the mean value plus 3 SD deviations for a control group of 20 BALB/c female mice. 
Radioimmunoassay for gp70 IC.  To determine the amounts of gp70  bound  to Ig, sera were 
depleted of Ig by absorption  with protein A-containing S. aureus (Staph A). 0.3  ml of serum 
diluted  1/120  in  borate  buffer  that  contained  0.01%  Triton  X-100  (Rohm  and  Haas  Co., 
Philadelphia, Pa.) was incubated with 0.025  ml washed, packed Staph A for 30 min at room 
temperature.  After the  precipitation of Ig-bound  Staph  A  by centrifugation, the amount  of 
gp70 in the supernate was determined by inhibiting the binding of goat anti-feline leukemia 
virus antibody  to  125I-labeled gp70  from  Rauscher  MuLV as  described  previously (1). As  a 
control, sera were treated with protein A-free Staph A. After comparing the concentrations of 
gp70 in both samples, the amounts of gp70 bound to Ig were calculated. The mean concentra- 
tions of Ig-bound gp70 in 20 serum samples from 2-too-old NZB ×  W and MRL/1 female mice 
were 2.2 +  2.5/Lg/ml and  1.5 +  2.4 #g/ml, respectively. 
Sucrose Density-Gradient Ultracentrifugation.  For determining the sedimentation characteristics 
of serum gp70, 0.2-ml samples diluted  1/4 in 0.01 M  PBS, pH 7.0, were layered on 5-20% (wt: 
vol)  linear sucrose density gradients in PBS. Samples were then centrifuged at 36,000  rpm for 
15 h at 4°C with a SW60 rotor in a Beckman L-75 ultracentrifuge (Beckman Instruments, Inc., 
Fullerton, Calif.). The positions of IgM, IgG, or gp70 were established by radioactive markers, 
then  the gradients were divided into  12 fractions. Each fraction was radioimmunoassayed for 
the presence of gp70. 
Quantitation of Serum Levels of C3 and Ig.  Serum levels of C3, IgG1, IgG2a, and IgG2b were 
measured by radial immunodiffusion in agar according to the method of Mancini et al.  (23). 
Serum C3 levels are expressed as a percentage of the normal pool values. 1648  SUPPRESSED  gp70 COMPLEX FORMATION BY  PROSTAGLANDIN E 
Statistical Analysis.  Statistical  analysis was performed  with  the Mann-Whitney U-test and 
the Wilcoxon two-sample test. 
Results 
Effect of PGE on Survival Rate and Renal Disease in NZB  X  W  Female Mice.  NZB ×  W 
female mice were treated with PGE beginning at 2 mo of age. As reported (8), 50% of 
the control females, which did not receive PGE, died by 10.2 mo of age and only 10% 
were alive at  1 yr. However, none of the mice treated with PGE died within the year. 
When evaluated for renal  histopathology after killing,  PGE-treated mice had less 
evidence of IC glomerulonephritis than controls throughout the experiments.  Repre- 
sentative values from  10-mo-old mice are shown in Table I. As determined by light 
microscopy, control animals had typical glomerular lesions character istic of this strain. 
These included an expansion of the mesangium caused by an increase in the number 
of cells and a thickening of the peripheral capillary loops. In contrast, animals treated 
with PGE had only minimal alterations.  By immunofluorescence, larger amounts of 
Ig and retroviral  gp70 accumulated in  glomeruli of control mice as compared with 
the PGE-treated group. This finding was further substantiated by electron microscopy 
(Table I): control mice had prominent electron-dense deposits in both the mesangial 
areas  and  the  peripheral  capillary  loops.  In  comparison,  PGE-treated  mice  had 
significantly fewer deposits, which were confined to the mesangium. 
A  considerable  amount  of gp70  (19.0  ~g/g of tissue)  was  demonstrable  in  renal 
elutes from  l-yr-old control NZB X W  female mice, whereas renal elutes from PGE- 
treated  mice of the same age and sex  contained significantly less gp70  (6.2/lg/g of 
tissue),  identical to the amount presumably present in the tubular brush borders of 2- 
mo-old healthy mice (5.0/~g/g of tissue).  In keeping with the reduced IC deposition 
in the glomeruli, the amount of IgG elutable from kidneys of PGE-treated mice was 
72/~g/g of tissue, only ~ 10% of that found in untreated controls (667/~g/g of tissue). 
In  spite  of the  reduced  IgG  deposition,  PGE-treated  mice  had  11  ~g  anti-DNA 
antibodies/g kidney vs. control levels  (30 ~g/g kidney). When considered in tcrms of 
specific activity, at the same concentration of IgG, the ssDNA- and dsDNA-binding 
activities of renal eluates  from PGE-treated mice were two and three times greater, 
respectively, than  those of untreated  mice.  Notably, anti-DNA antibodies were not 
detected in kidney homogenates of 2-mo-old mice. 
Anti-DNA  Antibodies  and  Circulating  IC in PGE-treated and  Control  NZB  X  W  Female 
Mice.  There were essentially no differences in  the serum  levels  of anti-ssDNA and 
anti-dsDNA antibodies, and  IgG in 4-mo-old and  10-mo-old PGE-treated mice and 
TABLE I 
Microscopic Studies of Kidneys in PGE-treated and Control lO-mo-old 
NZB  ×  W Female Mice 
PGE  Saline 
Light microscopy  1.1 -----  0.2*  3.5) __- 0.2 
Fluorescence microscopy 
lgG  1.2 + 0.5  3.1 + 0.2 
gp70  0  1.4 + 0.2 
Electron microscopy  1.2 ::t:  0.2  3.2 + 0.3 
* Grades of renal pathology. Mean ± SEM (10 mice in each group). S,  IZUI, V.  E,  KELLEY,  P,  J.  McCONAHEY,  AND  F.  J,  DIXON  1649 
controls,  despite  the  great  difference  in  their  survival  rates  and  degree  of renal 
destruction.  Representative results of serum ssDNA- and dsDNA-binding activity in 
8-mo-old animals of both groups are shown in Fig.  1. To establish the class of anti- 
ssDNA and anti-dsDNA antibodies, we added  2-ME, which  inactivates IgM, to the 
mixtures  being  tested  for  ssDNA  and  dsDNA  binding  activities.  However,  PGE- 
treated  and control  mice were equally resistant  to 2-ME  treatment  throughout  the 
test period  (Table II). Additionally,  pooled sera from 4- and 6-mo-old PGE-treated 
mice subjected to sucrose density-gradient ultracentrifugation had essentially identical 
levels of IgM and  IgG anti-ssDNA,  as well as anti-dsDNA  antibodies  as sera from 
untreated  mice of the same age and sex (data not shown). This analysis of the anti- 
DNA Ig class indicates  the similar age-dependent development of IgG antibodies to 
ssDNA and dsDNA in the PGE-treated and untreated animals. 
The avidity of anti-ssDNA antibodies in pooled sera of 8-mo-old NZB ×  W  female 
mice  in  PGE-treated  and  control  groups  was  then  compared  by determining  the 
relative dissociation rates. However, both groups of sera were essentially identical in 
this respect  (Table III). Thus,  the treatment  of NZB  X  W  mice with  PGE did  not 
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FIG.  1.  Serum ~5I-DNA binding activity in 8-mo-old PGE-treated and control NZB X W  female 
mice.  Bars represent the mean value of each examination. 
TABLE  II 
Sensitivity  of Anti-ssDNA and Anti-dsDNA Antibodies  to 2-ME in PGE-treated  and Control NZB  ×  W 
Female Mice 
Group  Age 
I~I-ssDNA binding*  I~I-dsDNA binding* 
Without 2-ME  With 2-ME  Without 2-ME  With 2-ME 
mo  %  % 
PGE  5  33.7  ±  10.4~  34.6 ±  16.3  12.7 ±  4.9  12.8 ±  5.4 
Saline  5  32.2 ±  14.9  29.3 ±  15.6  10.3 ±  4.4  10.0 ±  5.1 
PGE  8  55.7  ±  13.5  59.7 ±  17.5  21.5 ±  7.3  25.8 ±  10.3 
Saline  8  53.9  +  10.6  57.4  ±  19.0  18.3 ±  5.3  22.8  ±  8.1 
* 10 gtl of serum was incubated with 20 ng of ~2~I-DNA with or without 0.1  M  2-ME. 
:~ Mean of 10 mice ",- 1 SD. 1650  SUPPRESSED  gp70 COMPLEX  FORMATION BY  PROSTAGLANDIN E 
TABLE III 
Avidity of Anti-ssDNA  in PGE-treated and Control NZB ×  W Female Mice 
Avidity component§ 
Serum*  Avidity:]:  High  Low 
index 
Avidity component]l 
High  Low 
Percent  Percent  Percent  Percent  min  min  h  min  of tl/2  of tl/2  of tl/2  of tl/2 
PGE  4.19  84  >100  16  1.5  61  >48  39  24 
Saline  4.37  84  >100  16  1.2  63  >48  37  24 
* Pooled sera from l0 8-mo-old mice.  (  l  ) 
t: Avidity index =  % dissociation at 30 minl  x  100. 
§ Resolution of the dissociation curves into the high- and low-avidity components from data points obtained 
over 30-min dissociation periods. 
II Resolution of the dissociation curves into the high- and low-avidity components from data points obtained 
over 30-h dissociation periods. 
appear to alter either the quality or the quantity of anti-DNA antibodies, although 
PGE was effective in delaying glomerulonephritis and prolonging this strain's survival. 
The presence of DNA-anti-DNA IC in sera of PGE-treated and control NZB X  W 
mice was  investigated by three  different  methods  that  can  efficiently detect  DNA- 
anti-DNA IC  in sera (20-22).  However, none of the techniques  demonstrated  meas- 
urable amounts of DNA-anti-DNA IC in sera from either groups of mice throughout 
the course of experiments (data not shown). 
However, when  serum  levels of IC detectable by Raji cell assay were compared in 
PGE-treated and control mice, tested at 8-mo of age, concentrations were abnormally 
high in both groups. The control NZB X  W  mice had mean IC levels of 126/~g with 
100%  of the animals having values above normal.  Comparatively, the  PGE-treated 
mice had a somewhat lower but still increased IC concentrations of 88/~g, representing 
93% of animals above normal. 
Although the PGE-treated mice had considerable amounts of circulating IC, serum 
concentrations of C3 were still high.  In the 8-too-old mice, mean values were 81.0  + 
17.4% (+  1 SD) of normal pooled values, which were comparable to those of 2-mo-old 
NZB X W  mice (96.3 +  19.1%), indicating no significant consumption of complement 
in the PGE-treated mice. By contrast, serum levels of C3 were greatly suppressed in 
the untreated  mice. The mean values of 8-mo-old control NZB  ×  W  mice were only 
43.2 +  14.1%. 
Retroviral  gp70  IC  in  PGE-treated  and  Control  NZB  X  W  mice.  We  previously 
demonstrated (1) that only sera from mice of SLE-prone strains, including NZB ×  W 
mice, contain  a  rapidly sedimenting heavy  form  of gp70 complexed to  Ig, that  the 
appearance of these  IC  parallels the  onset  of renal  disease and  that  the complexes 
persist throughout  the course of disease. Therefore, we next examined the presence of 
circulating gp70 IC in the PGE-treated mice by determining the sedimentation rate 
of serum gp70 and by quantitating absorption of Ig-complexed gp70 with Staph A. 
After sucrose density-gradient ultracentrifugation, pooled sera from 5-too-old con- 
trol NZB X W  mice contained significant amounts ofgp70 in fractions that contained 
material  heavier than  7S  IgG  (Fig.  2).  In  pooled  sera  from  8-mo-old control  mice, 
even larger amounts of gp70 appeared in the heavy fractions. In contrast, of NZB  X S.  IZUI, V.  E.  KELLEY,  P.  J.  McCONAHEY,  AND  F. J.  DIXON  1651 
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FIG.  2.  Sedimentation rate of serum gp70 from PGE-treated (0) and control (O) NZB X W female 
mice at 5 and 8 mo of age analyzed by sucrose density-gradient ultracentrifugation. The concentra- 
tion of gp70 was determined by the radioimmunoassav, The positions of markers are indicated by 
arrows. 
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FIG.  3.  Serum  concentrations of Ig-bound gp70 in  PGE-treated  and control  NZB ×  W female 
mice as determined by radioimmunoassay combined with Staph A absorption. The mean values are 
indicated by the horizontal line. 
W  mice treated with PGE, the heavy form of gp70 was detectable only in the 8-mo- 
old  group.  Even  then,  less  heavy gp70  was  apparent  than  in  untreated  NZB  ×  W 
mice of the same age. 
To compare the  levels of gp70  IC in  PGE-treated and  control mice more quanti- 
tatively, we measured amounts of gp70 present before and after Ig was removed from 
the sera with Staph A. The quantities of Ig-bound gp70 were significantly higher in 
untreated  control mice than  in  those treated  with  PGE  (Fig.  3  and Table IV). As a 
result of absorption, in the control group 64% of sera from 6-mo-oid mice and >90% 
of the sera from 8- to  10-mo-old mice lost more than  one-fifth of their gp70 content. 
In  contrast,  when  tested  at  6,  8,  and  even  10  mo of age, <20%  of the  PGE-treated 
mice had  significant  amounts  (more  than  one-fifth)  of gp70  complexed with  Ig.  It 1652  SUPPRESSED  gp70 COMPLEX  FORMATION BY  PROSTAGLANDIN E 
TAaLE  IV 
Serum Levels of Total gp 70 and Ig-bound gp 70 in PGE-treated  and Control NZB  ×  W 
Female Mice 
Percent of Ig- 
Treatment  Age  n  Total gp70*  Ig-bound gp70*  bound gp70 of 
total gp70 
mo  gg/ml  I~g/rnl 
PGE  6  18  39.3+  11.1  3.6+  4.2~  9.3+  11.3§ 
Saline  6  14  37.7 ::t: 12.6  15.7 +  14.4:~  36.7 + 27.4§ 
PGE  8-10  34  50.2 ±  15.3  5.9:1=  7.411  11.8 +  12.81[ 
Saline  8-10  43  45.7 +  16.9  19.1 ±  1o.811  41.1 ±  14.211 
* All the values represent mean +  1 SD. 
,  P< 0.01. 
§ P < 0.005. 
tl P < 0.001. 
should be noted that the total concentrations of gp70 detectable in sera were similar 
in treated and control mice (Table IV). 
To examine the possibility that  PGE  present  in sera from  the treated mice might 
have  interfered  with  the  absorption  of Ig-bound  gp70  by  Staph  A,  serum  samples 
from  8-mo-old  NZB  X  W  mice  containing  considerable amounts  of Ig-complexed 
gp70 were absorbed with Staph A  in the presence of various concentrations of PGE 
(0.001-100  ~g/ml  in  serum).  Regardless of the concentrations  tested,  PGE  did  not 
interfere with the absorption of gp70 IC by Staph A  (data not shown). 
Effect on PGE on MRL/1  and BXSB  Mice.  The effect of PGE on the development of 
the  renal  disease, anti-DNA antibodies and  gp70  IC  was  then  tested  in  two  newly 
developed strains, MRL/1  and male BXSB mice, which are predisposed to SLE. Both 
strains received PGE injections beginning at 2 mo of age, just as the NZB X  W  mice 
did. The effect of PGE on  MRL/1  mice was dramatic;  survival times was markedly 
prolonged (at 8 mo of age, 90% of the PGE-treated female mice were alive--all of the 
female controls were dead), and  the development of glomerulonephritis was  greatly 
suppressed.  The  retardation  of renal  disease was  reflected  in  histologic grades;  the 
mean  grades of controls were 3.7,  whereas treated mice reached a  mean of only  1.1. 
In addition, the treatment prevented lymphoproliferation compared to that in controls 
(Table V). However, there was no significant difference in serum  levels of anti-DNA 
antibodies, although slightly less IgG1 was observed in the PGE-treated mice (Table 
V).  The  details  of this  experiment  will  be  described  elsewhere.  (V.  E.  Kelley, A. 
Winkelstein,  S.  Izui,  and  F. J.  Dixon.  Manuscript  in  preparation.)  When  the  two 
groups of sera were compared  for the presence of Ig-complexed gp70,  the incidence 
and  quantities  of gp70  IC  were  significantly higher  in  untreated  mice  than  in  the 
PGE-treated mice (Table VI). 75% of sera from 4-mo-old untreated female mice had 
significant amounts  (more than  one-fifth) of gp70 complexed with  Ig, but only 25% 
of sera from  the PGE-treated mice contained significant amounts of Ig-bound gp70. 
Results were  similar in  male  MRL/1  mice  (Table VI).  Substantial  amounts  (more 
than  one-fifth)  of gp70  bound  to  Ig were  observed  in  55%  of sera  from  4-mo-old 
untreated male mice, compared with only 12% of the PGE-treated mice. Nevertheless, 
such treatment did not significantly affect the total serum levels of gp70. S.  IZUI,  V.  E.  KELLEY,  P. J.  McCONAHEY,  AND  F.  J.  DIXON 
TABLE  V 
Effect of PGE Treatment on Lymphoadenopathy and Serum Levels of IgG and 
Anti-DNA in MRL/ I Female Mice 
PGE  Control 
Lymphoadenopathy  2/20  20/20 
igG~ 
IgG1  2.99 ±  2.18§  6.42 +  1.56§ 
IgG2a  11.69  -t-  2.9611  13.76 ±  5.0011 
IgG2b  1.05 +  0.3511  1.59 +  0.8811 
Anti-dsDNA§  12.2  ±  7.511  14.5  ±  9.811 
Anti-ssDNA:~  41.9  ±  20.411  49.1  ±  17.411 
* Number positive/number tested up to 4 mo of age. 
:~ Serum levels of IgG (mg/ml) and anti-DNA antibodies were determined in 
4-rap old animals. Anti-dsDNA activity is expressed as the mean percentage 
of 20  ng  lz~I-DNA  precipitated  specifically  by  10  #1  serum.  Anti-ssDNA 
activity is expressed as the mean percentage of 20 ng ~25I-DNA precipitated 
by 2 #1 serum. Results indicate mean values ±  1 SD of 20 PGE-treated and 
17 control mice. 
§P<  0.01. 
liP>0.1. 
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TABLE  V[ 
Serum Levels of Total gp70 and Ig-bound gp70 in PGE-treated and Control 4-too-old MRL/1 Mice 
Percent Ig-bound 
Treatment  Sex  n  Total gp70*  Ig-bound gp70*  gp70 of total gp70 
~g/ml  I~g/ml 
PGE  Female  20  17.7 ±  9.3  3.4 ±  5.0:1:  18.6 ±  18.8~ 
Saline  Female  17  21.0 ±  9.5  10.0 ±  9.9:1:  38.6 ±  25.7:1: 
PGE  Male  17  22.8 ±  10,5  1.4 +  2,6§  6.5 ±  10.5~: 
Saline  Male  20  26.9 ±  12.3  9.2 +  8.1§  30.4 +  26.2:~ 
* All the values represent mean ±  1 SD. 
:~ P <  0.005. 
§ P<  0.001. 
In  contrast,  the  BXSB  males  remained  unchanged  by  treatment  with  PGE  in 
respect to survival or development of renal disease. One-half of the PGE-injected and 
untreated  BXSB  mice alike  died  of glomerulonephritis  before 6  mo of age.  Their 
serum levels of gp70 IC at 4-5 mo of age were essentially identical:  PGE-treated 5.7 
+  3.9/~g/ml, untreated 6.3 +  5.7/xg/ml, P. >  0.1. 
Discussion 
In NZB X W  mice, PGE modulates the expression of SLE (7, 8). The development 
of IC glomerulonephritis  is suppressed, and survival is greatly prolonged.  PGE also 
prevents the development of fatal glomerulonephritis and massive lymphoprolifera- 
tion  that  accompanies the  SLE of MRL/1  mice, but  does not  protect  BXSB  mice 
from similar lupus-like disease. 
Despite the beneficial effects of PGE in lessening renal pathology and lengthening 
life span in NZB X W  and MRL/1  mice, their production of anti-ssDNA and anti- 1654  SUPPRESSED  gp70 COMPLEX FORMATION  BY PROSTAGLANDIN E 
dsDNA remains virtually unchanged. Because the qualitative and quantitative aspects 
of the  anti-DNA  response  in  murine  SLE  may be equally  important  in  provoking 
renal disease, PGE might function by suppressing the formation of a specific subpop- 
ulation(s) of anti-DNA antibodies that is more pathogenic than others. In fact, recent 
studies  suggest  that  SLE  strains  of  mice  develop  new  clonotypes  of  anti-DNA 
antibodies  coinciding  with  the onset  of renal  disease  (24).  Further,  the avidity and 
isotype  of  anti-DNA  antibodies  may  be  as  important  as  their  quantities  in  the 
development  of tissue  lesions  in  patients  with  SLE  as  well  as  lupus  mice  (25-27). 
However, we  found  no  qualitative  differences  in  the  isotypes or avidities  of serum 
anti-DNA antibodies in PGE-treated and untreated mice. Apparently, PGE achieves 
its therapeutic effect through mechanisms that do not directly involve the formation 
of anti-DNA  antibodies.  It  should  be  noted  that  other  forms of therapy  that  can 
prolong survival in NZB ×  W  mice also act without altering anti-DNA levels (28-30). 
The  most  significant  observation  in  the  present  study  is  that  the  incidence  and 
quantity of Ig-complexed gp70 are lower in the sera of NZB ×  W  and MRL/1  mice 
treated  with  PGE  than  in  those  of  untreated  mice.  This  was  demonstrated  by 
measuring  amounts  of the  heavy form of serum  gp70,  which  is  composed of gp70 
complexed with anti-gp70 antibodies (1), and by the quantitative absorption of serum 
gp70 IC with Staph A, which effectively removes both IC and IgG from serum  (31, 
32).  Such  decreases  in serum gp70 IC were found  in  PGE-treated mice throughout 
the course of these experiments. Adding PGE directly to sera that contained gp70 IC 
did not affect our ability to quantitate the free or complexed forms of gp70, thereby 
ruling out the possible interference of PGE in this assay. Of course, PGE-treated mice 
might develop as many gp70 IC as untreated mice but may clear these IC selectively 
from circulating blood by activating the mononuclear phagocytic systems. However, 
it is difficult to conceive that gp70 IC alone are cleared from the circulation, because 
relatively large amounts of other IC are present in sera from the PGE-treated mice. 
This study clearly shows that the decreased quantities and incidences of circulating 
gp70 IC in the PGE-treated mice correlate well with the reduced deposition of IC in 
the glomeruli. In the kidneys of PGE-treated SLE mice, as in immunologically normal 
mice  (33),  gp70 was seen by direct  immunofluorescence only in  the tubules,  but  in 
untreated SLE mice, glomeruli as well as tubules were involved (2, 3). The amount of 
gp70 eluted  from kidneys of l-yr-old PGE-treated mice was one-third  that  from the 
control mice but similar to that from young healthy mice of the same strain and sex. 
The low complement consumption in PGE-treated mice, documented by the high C3 
levels  in  their  sera,  may  have  resulted  from  the  reduced  levels  of circulating  and 
kidney-bound  gp70  IC.  This  association  of circulating  gp70  IC with  renal  disease 
strongly suggests the importance of gp70 IC in  the development of fatal glomerulo- 
nephritis in murine SLE. Furthermore, serum levels of gp70 IC were not decreased in 
PGE resistant  BXSB mice, a  fact that supports the primary involvement of gp70 IC 
in the renal lesions of SLE mice. 
Our observation, however, does not preclude the involvement of IC other than gp70 
IC  in  the  renal  disease  of  SLE  strains.  These  mice  produce  large  amounts  of 
unidentified  IC-like materials that  are detectable by the Raji cell assay, the conglu- 
tinin-binding  assay,  and  the  anti-C3  solid-phase  radioimmunoassay  (3,  34,  35). 
Although the PGE-influenced decrease in serum levels of IC may result at least partly 
from actual  depression  of gp70  IC levels, PGE may also suppress  the  formation of S.  IZUI, V. E.  KELLEY, P. J.  McCONAHEY, AND F. J.  DIXON  1655 
other forms of pathogenic IC such as DNA-anti-DNA IC by preventing the release of 
nuclear DNA antigens in circulating blood or in extravascular spaces without affecting 
the  production of anti-DNA  antibodies.  The renal  eluates  from  PGE-treated mice 
contained  less,  but  still  considerable  amounts  of anti-DNA  antibodies.  Moreover, 
anti-DNA  antibodies  in  these  eluates  were  more  concentrated  than  those  from 
untreated  mice, apparently  resulting from reduced deposition of other types of IC 
such as gp70 IC. The comparatively lesser amounts of DNA-anti-DNA  IC in PGE- 
treated mice might also be a  result of a  reduction in renal damage caused by other 
IC, resulting in the decreased release of DNA locally in glomeruli. Finally, one cannot 
exclude the possibility that PGE may alter renal hemodynamics and thereby reduce 
the deposition rate of circulating IC (36). 
The mechanisms by which PGE diminishes gp70 IC formation in circulating blood 
have not been defined. However, the possibility that  PGE lessens  the expression of 
xenotropic viral gp70 in serum is unlikely because serum levels of total gp70 in PGE- 
treated mice are as high  as  in  untreated  mice. Of course, one cannot exclude that 
PGE  might  inhibit  the  production  of a  unique  and  as  yet  undiscovered  form  of 
retroviral gp70 that may be responsible for the formation of gp70 IC. However, recent 
studies  (S.  Izui, J.  H.  Elder,  P.  J.  McConahey,  and  F.  J.  Dixon.  Manuscript  in 
preparation.) of tryptic peptide maps of gp70 isolated from the circulating IC revealed 
its xenotropic nature, i.e., as not being different from the xenotropic gp70 normally 
found in sera of all SLE-prone and normal mice (37). This indicates that the formation 
of gp70 IC in SLE mice does not involve unique gp70, but  instead results from the 
unique ability to make antibody to this ubiquitous molecule. Therefore, it  is more 
likely that PGE inhibits the immune response to this endogenous viral antigen. The 
probability that  PGE modulates immune responsiveness to xenotropic viral gp70 is 
exemplified by the relative absence of lymphoid hyperplasia in PGE-treated NZB x 
W  and MRL/1  mice (38, 39). Moreover, PGE exerts its immunosuppressive effect in 
a somewhat selective manner, because only IgG1 is suppressed in PGE-treated MRL/ 
1 mice without  affecting IgG2a  production.  It should  be  noted  that  such  selective 
suppression  is compatible with the observation that  serum  levels of anti-DNA anti- 
bodies are unchanged by PGE treatment, because most  of anti-DNA  antibodies in 
MRL/1 mice belong to IgG2a subclass (18). Considering that PGE seems to decrease 
anti-gp70 antibody formation, these anti-gp70 antibodies might belong mainly to the 
IgG1 subclass in MRL/1 mice. If so, immune responsiveness to xenotropic viral gp70 
must  be  regulated  by  a  different  mechanism  than  governs  anti-DNA  antibody 
production and, thereby, PGE could selectively prevent the formation of anti-xeno- 
tropic viral gp70 antibodies. Indeed, the separation of anti-DNA formation and gp70 
IC formation in mice with SLE is supported by the following evidence. First, BXSB 
mice, which have only slightly elevated levels of anti-DNA antibodies, develop gp70 
IC earlier than  NZB  ×  W  mice whose much higher levels of anti-DNA  antibodies 
appear early in life (3).  Second, in preliminary studies, MRL/1  mice infected with 
lactic dehydrogenase virus have ~ 10 tin es fewer anti-DNA antibodies than uninfected 
control  mice, but  both  have similar  levels of gp70  IC.  Consequently,  independent 
regulatory mechanisms may be responsible for these two immune responses. 
Summary 
The effect of pharmacologic quantities of prostaglandin E~ (PGE) was investigated 
in  three  strains  of mice  (NZB  ×  NZW,  MRL/1,  and  BXSB)  that  spontaneously 1656  SUPPRESSED  gp70 COMPLEX  FORMATION BY  PROSTAGLANDIN E 
develop  lupus-like  glomerulonephritis.  PGE-treatment  prolonged  survival  and  re- 
tarded  the glomerular deposition of immune  complex  (IC)  and  the development of 
glomerulonephritis in NZB  ×  NZW and MRL/1  mice, but did not similarly protect 
BXSB mice. Changes in the responsive strains correlated well with reduced amounts 
of circulating gp70 complexed with  anti-gp70 antibodies compared with  untreated 
controls,  although  total  concentrations  of gp70  (free and  complexed)  detectable in 
sera were similar in both groups of mice. The results strongly suggest  that:  (a)  PGE 
selectively suppressed  the  immune  response  to  retroviral  gp70,  (b)  PGE  had  little 
effect on the quantity or quality ofanti-DNA antibodies but did reduce the deposition 
of  anti-DNA  containing  IC  in  the  kidneys,  and  (c)  gp70  IC  appear  to  play  an 
important  role  in  the  pathogenesis  of glomeruionephritis in  murine  systemic lupus 
erythematosus. 
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